脾切除术是成人难治性免疫性血小板减少症的良好策略吗
本文综述了脾切除术治疗成人免疫性血小板减少症(ITP)的近期数据,重点关注其长期耐受性、副作用以及疗效预测因素,尤其是对多线药物治疗失败患者的疗效预测。尽管当前多数指南将脾切除术、利妥昔单抗和血小板生成素受体激动剂(TPO-RAs)置于同一治疗等级,但临床医生和患者倾向于推迟手术。本文旨在帮助医患在多线治疗失败时,基于最新数据对脾切除术的指征做出知情决策。
要点
- 多数指南将脾切除术、利妥昔单抗和TPO-RAs置于同一治疗等级,但临床实践倾向于推迟脾切除术。
- 脾切除术实施频率下降,原因包括对严重晚期感染和深静脉血栓等并发症的认识提高,以及无法可靠预测其有效性。
- 对多线药物治疗失败的患者,脾切除术的有效性风险缺乏充分证据,影响决策。
核心结论
- 本更新旨在综述脾切除术的长期耐受性、副作用及疗效预测因素的最新数据,以帮助医患在多线治疗失败时对脾切除术指征做出知情决策。
研究设计与样本
- 本文为叙述性综述,检索并汇总了关于脾切除术治疗成人ITP的长期耐受性、副作用及疗效预测因素的最新发表数据。
主要发现
- 过去20年,利妥昔单抗和TPO-RAs深刻改变了ITP的管理。
- 尽管多数指南将脾切除术、利妥昔单抗和TPO-RAs置于同一治疗等级,但多数临床医生和患者明显倾向于推迟脾切除术,并在考虑手术前增加多线药物治疗。
- 脾切除术目前实施频率大幅降低,原因包括对其并发症(尤其是严重晚期感染和深静脉血栓)的认识提高,以及无法可靠预测其有效性。
- 当其他治疗无效时,基于脾切除术可能无效的风险(证据不充分),存在不愿推荐脾切除术的倾向。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rituximab and thrombopoietin receptor agonists (TPO-RAs) have profoundly changed the management of immune thrombocytopenia (ITP) over the last 20 years. Even if most current guidelines put splenectomy, rituximab and TPO-RAs on the same treatment level, most clinicians and patients clearly prefer to postpone splenectomy and to multiply the lines of medical treatment before considering surgery. The management of ITP refractory to rituximab and TPO-RAs is challenging. Splenectomy is currently performed much less frequently because of a better knowledge of its complications, particularly severe late infections and deep vein thrombosis, and the inability to reliably predict its effectiveness. Furthermore, there is a reluctance to propose splenectomy when other treatments have been ineffective, based on the not well-documented risk that splenectomy could not be effective in such a case. The objective of this update was to review the most recent published data on the long-term tolerability and side effects of splenectomy and the predictors of response and efficacy, especially for patients exposed to multiple medical lines. This update can help physicians and patients with failure of multiple lines of therapy make an informed decision on the indication for splenectomy with the help of up-to-date data.
引用
- Godeau B. Is splenectomy a good strategy for refractory immune thrombocytopenia in adults? Br J Haematol. 2023. PMID: 37735555. doi:10.1111/bjh.19077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。